- On July 22, both The Jerusalem Post and Forbes reported that Oravax Medical's oral COVID vaccine candidate is about to begin a phase 1 trial in Israel.
- While Israel is said to be "first in world" to test "Oravax" oral COVID vaccine, Vaxart, a US-based company, has completed a phase 1 trial of their oral COVID vaccine.
- Vaxart is about to begin a phase 2 trial, possibly in South America, aiming to determine the optimal dosing schedule for going forward.
- An oral COVID vaccine, if successfully developed, is a game changer for ending the pandemic globally.
- For investors who have appropriate risk tolerance and time frame, Vaxart is a BUY!
For further details see:
Vaxart: World's First Oral COVID Vaccine In Development